Risk factors
Genprex (GNPX) risk factors
Item 1A of every Genprex, Inc. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
75 risks, 1 new, 1 dropped, 10 reworded since the prior year. Genprex relies heavily on ongoing equity sales under its ATM agreement to fund operations into the second quarter of 2027.
Filed Mar 30, 2026 - FY2024 10-K risk factors
75 risks. Genprex faces going concern doubts with an accumulated deficit of approximately $154.8 million as of December 31, 2024. The business relies heavily on the clinical success of lead drug REQORSA and preclinical candidate GPX-002. Operations depend entirely on third-party CDMOs for manufacturing and CROs for clinical trial execution.
Filed Apr 01, 2025